Please login to the form below

Not currently logged in
Email:
Password:

Vemlidy

This page shows the latest Vemlidy news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Current HBV therapies, including Gilead’s own Hepsera, Viread and Vemlidy, focuses on inhibiting viral DNA replication but don't completely clear the virus.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... Confirming the CHMP's November approval recommendation, the EC

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of adults and adolescents ... The CHMP's recommendation follows the

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics